Необязательная аналитика продукта
С вашего разрешения мы используем ограниченную аналитику с защитой конфиденциальности, чтобы понять, какие исследовательские сценарии работают. Мы не используем рекламные трекеры или запись сеансов. Этот выбор можно изменить в настройках. Прочитайте Политику конфиденциальности.
Becton Dickinson and Company's published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $48.2B | |
|---|---|---|
| Revenue (ttm) | 22.5B | |
| Net income (ttm) | 942M | |
| EPS (ttm) | $3.33 | |
| Shares out | 272.4M | |
| P/E (trailing) | 58.5x | |
| P/E (forward) | 13.7x | |
| Dividend | $4.20 (2.16%) | |
| Volume | 1,351,015 | |
| Beta | 0.28 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2026-09-30 | Trend |
| Revenue | $18.87B | $19.37B | $20.18B | $21.84B | — | +5.0% |
| Gross profit | $8.48B | $8.17B | $9.13B | $9.92B | — | +5.4% |
| Operating income | $2.28B | $2.11B | $2.40B | $2.58B | — | +4.2% |
| Net income | $1.78B | $1.48B | $1.71B | $1.68B | — | -1.9% |
| EPS (diluted) | $4.62 | $3.88 | $4.61 | $4.58 | $9.04 | +18.3% |
| EBITDA | $4.41B | $4.40B | $4.82B | $4.96B | — | +4.0% |
| R&D | $1.26B | $1.24B | $1.19B | $1.27B | — | +0.2% |
| SG&A | $4.71B | $4.72B | $4.86B | $5.28B | — | +3.9% |
Recent company headlines from major financial publishers.
The Base scenario envisions steady hospital procedure replenishment supporting core Medical and Interventional consumable franchises. Operational execution through productivity programs counterbalances selective group purchasing pricing concessions, while international markets compound at moderate single-digit rates. With the shares trading at $176.80 against our Fair value of $194.59, this outcome carries a target of $194.59 at an assigned probability of 55.0%, implying an expected return of 10.1%. Disconfirmation would emerge if core consumable volume growth turns negative or if operating margins slip below targeted levels within the next fiscal year.
The Bull scenario reflects sustained market share capture from competitor supply disruptions, accelerating Medical segment volume growth alongside expanding international adoption. Manufacturing automation and operating leverage widen operating margins toward peer benchmark levels, driving accelerated free cash flow that substantially expedites debt retirement. This upside path yields a target of $323.86 with an assigned probability of 20.0%, representing a return of 83.2% toward Potential value of $323.86. Disconfirmation would occur if competitor capacity quickly restores customer volume share or if hospital capital spending slows within the next two fiscal years.
| Ke ↓ / g → | 1.7% | 2.0% | 2.2% | 2.5% | 2.7% |
|---|---|---|---|---|---|
| 6.2% | $210 | $215 | $221 | $229 | $237 |
| 6.7% | $198 | $202 | $206 | $212 | $218 |
| 7.2% | $188 | $191 | $195 | $199 | $203 |
| 7.7% | $179 | $182 | $185 | $188 | $192 |
| 8.2% | $172 | $174 | $177 | $179 | $182 |
Upcoming earnings date and setup when available.
Рейтинг, который имело опубликованное в каждом месяце издание исследования. Рейтинг сравнивает цену на дату анализа со справедливой стоимостью; он не показывает, оправдалась ли оценка.
| Год | янв. | февр. | март | апр. | май | июнь | июль | авг. | сент. | окт. | нояб. | дек. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
